Central Pharmaceuticals Ltd. (DSE:CENTRALPHL)
Bangladesh · Delayed Price · Currency is BDT 11.20
-0.20 (-1.75%)
At close: Aug 13, 2026
Central Pharmaceuticals Balance Sheet
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash & Equivalents | 1.24 | 1.23 | 1.76 | 1.19 | 1.53 | 3.08 |
Cash & Short-Term Investments | 1.24 | 1.23 | 1.76 | 1.19 | 1.53 | 3.08 |
Cash Growth | - | -29.99% | 47.79% | -22.02% | -50.27% | -24.89% |
Receivables | 69.36 | 68.9 | 73.25 | 80.4 | 79.1 | 79.05 |
Inventory | 16.25 | 22 | 17.79 | 21.6 | 39.7 | 61.4 |
Other Current Assets | 287.06 | 287.06 | 287.06 | 287.06 | 286.82 | 287.06 |
Total Current Assets | 373.91 | 379.2 | 379.87 | 390.24 | 407.16 | 430.58 |
Property, Plant & Equipment | 1,035 | 1,050 | 1,061 | 877.48 | 904.23 | 933.99 |
Other Intangible Assets | 0.08 | 0.08 | 0.09 | 0.1 | 0.11 | 0.13 |
Other Long-Term Assets | - | - | - | 0 | - | 0.13 |
Total Assets | 1,409 | 1,429 | 1,441 | 1,268 | 1,312 | 1,365 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Accounts Payable | 27.77 | 19.25 | 8.46 | 5.29 | 1.5 | 0.65 |
Accrued Expenses | 0.7 | 1.13 | 0.62 | 0.81 | 0.41 | 0.68 |
Short-Term Debt | - | - | 0.3 | - | - | - |
Current Portion of Long-Term Debt | 36.5 | 36.5 | 36.5 | 36.5 | 36.5 | 27.37 |
Current Income Taxes Payable | 280.74 | 280.58 | 280.38 | 280.2 | 280.02 | 279.87 |
Other Current Liabilities | 6.82 | 6.82 | 6.82 | 6.82 | 6.82 | 6.83 |
Total Current Liabilities | 352.53 | 344.27 | 333.07 | 329.62 | 325.25 | 315.39 |
Long-Term Debt | 231.98 | 231.98 | 231.98 | 231.98 | 231.98 | 224.06 |
Long-Term Deferred Tax Liabilities | 29.39 | 29.39 | 30.31 | 36.36 | 40.44 | 43.17 |
Other Long-Term Liabilities | -21.67 | -0 | - | -0 | - | - |
Total Liabilities | 592.22 | 605.64 | 595.36 | 597.95 | 597.67 | 582.62 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Common Stock | 1,198 | 1,198 | 1,198 | 1,198 | 1,198 | 1,198 |
Retained Earnings | -1,114 | -1,107 | -1,085 | -1,043 | -999.02 | -930.64 |
Comprehensive Income & Other | 732.69 | 732.69 | 732.69 | 514.85 | 514.85 | 514.85 |
Shareholders' Equity | 816.86 | 823.32 | 845.3 | 669.88 | 713.83 | 782.21 |
Total Liabilities & Equity | 1,409 | 1,429 | 1,441 | 1,268 | 1,312 | 1,365 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Total Debt | 268.47 | 268.47 | 268.77 | 268.47 | 268.47 | 251.43 |
Net Cash (Debt) | -267.23 | -267.24 | -267.01 | -267.28 | -266.94 | -248.36 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -2.23 | -2.23 | -2.23 | -2.23 | -2.23 | -2.07 |
Filing Date Shares Outstanding | 119.8 | 119.8 | 119.8 | 119.8 | 119.8 | 119.8 |
Total Common Shares Outstanding | 119.8 | 119.8 | 119.8 | 119.8 | 119.8 | 119.8 |
Working Capital | 21.38 | 34.93 | 46.8 | 60.63 | 81.91 | 115.19 |
Book Value Per Share | 6.82 | 6.87 | 7.06 | 5.59 | 5.96 | 6.53 |
Tangible Book Value | 816.78 | 823.23 | 845.21 | 669.77 | 713.72 | 782.09 |
Tangible Book Value Per Share | 6.82 | 6.87 | 7.06 | 5.59 | 5.96 | 6.53 |
Land | 856.42 | - | - | 638.58 | - | - |
Buildings | 188.01 | - | - | 188.01 | - | - |
Machinery | 628.17 | - | - | 628.17 | - | - |